Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

A monthly supply of generic versions of Novo Nordisk’s (NVO) GLP-1 therapy, semaglutide, marketed as Ozempic and Wegovy, could cost less than $3 per person, according to a new study posted this week.

Feb 12 (Reuters) - West Pharmaceutical (WST.N), opens new tab forecast annual profit above Wall Street estimates on Thursday, banking on higher demand for diabetes and obesity treatments that use its ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company plans to use an ...

Cuban said the high fees the FDA charges to approve generic drugs are a major barrier to manufacturing lower-priced generics in the United States, according to the report. Cuban said Cost Plus Drugs, ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

Incyte Corporation is undervalued, with high revenue growth, strong margins, and a 12.7% upside to a $115 target price; rated Buy. INCY's Q3 results beat expectations, driven by Jakafi and Opzelura ...

AFTER AMERICA, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s clinical trials last year. That is up from just 5% a decade before (see chart 1 ...